Evidence map›Paper›PMID 26186692›Full record

ArticlePloS one2015

Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine.

Chien-Chiao Huang, Kung-Kai Kuo, Ta-Chun Cheng, Chih-Hung Chuang, Chien-Han Kao, Yuan-Chin Hsieh, Kuang-Hung Cheng, Jaw-Yuan Wang, Chiu-Min Cheng, Chien-Shu Chen and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Chien-Chiao HuangDepartment of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Kung-Kai KuoDepartment of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Ta-Chun ChengDepartment of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan; Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan.
Chih-Hung ChuangDepartment of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan; Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chien-Han KaoDepartment of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan.
Yuan-Chin HsiehGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Kuang-Hung ChengInstitute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan.
Jaw-Yuan WangGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chiu-Min ChengDepartment of Aquaculture, National Kaohsiung Marine University, Kaohsiung, Taiwan.
Chien-Shu ChenSchool of Pharmacy, China Medical University, Taichung, Taiwan.
Tian-Lu ChengDepartment of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, Kaohsiung, Taiwan; Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan.
Kaohsiung Medical University · TWNational Sun Yat-sen University · TWChina Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of effective adjuvant is the key factor to boost the immunogenicity of tumor cells as a tumor vaccine. In this study, we expressed membrane-bound granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-18 (IL-18) as adjuvants in tumor cells to stimulate immune response. B7 transmembrane domain fused GM-CSF and IL-18 was successfully expressed in the cell membrane and stimulated mouse splenocyte proliferation. Co-expression of GM-CSF and IL-18 reduced tumorigenesis (P<0.05) and enhanced tumor protective efficacy (P<0.05) significantly in comparison with GM-CSF alone. These results indicated that the combination of GM-CSF andIL-18 will enhance the immunogenicity of a cell-based anti-tumor vaccine. This membrane-bound approach can be applied to other cytokines for the development of novel vaccine strategies.

Indexed as

AnimalsCancer VaccinesCarcinogenesisCell Line, TumorCell MembraneGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-18MiceVaccines, SyntheticCancer VaccinesGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-18Vaccines, Synthetic

Identifiers

PMID26186692
PMCPMC4506079
OpenAlexW1226859623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.